Owing to the promising results, Craft et al. conducted a large-scale, 12-month, phase 2/3 evaluation of 40 IU intranasal insulin per day in 289 patients with a diagnosis of MCI or AD [161]. This evidence concerns the gene INS and Alzheimer disease.